Biogen Idec’s Tecfidera Goes To Market With Claim For Delay Of Disability Progression
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved the oral multiple sclerosis drug March 27 to treat patients with relapsing forms of the disease. Labeling includes data from one trial that showed patients on Tecfidera experienced disability progression less often.
You may also be interested in...
With Tecfidera, Biogen Idec Delivers Best MS Product Launch Yet
Biogen Idec blew past Wall Street estimates in its first quarter of revenue for its new, oral multiple sclerosis drug. But the biotech attributed much of the unexpected upside to quick conversions from another of its MS products, Tysabri.
Alkermes Moves Beyond Reformulations As It Preps Three New Compounds For Clinic
Alkermes multi-year efforts to move up from its successful reformulations for partners takes a step forward as the biotech presents its expanding clinical pipeline to investors, highlighting early-stage compounds for multiple sclerosis, pain and cancer.
Alkermes Moves Beyond Reformulations As It Preps Three New Compounds For Clinic
Alkermes multi-year efforts to move up from its successful reformulations for partners takes a step forward as the biotech presents its expanding clinical pipeline to investors, highlighting early-stage compounds for multiple sclerosis, pain, and cancer.